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Objectives Clostridioides difficile infection (CDI) is a considerable healthcare and economic 27 
burden worldwide. Faecal microbial transplant remains the most effective treatment for CDI, 28 
but is not at the present time the recommended standard of care. We hereby investigate which 29 
factors derived from a healthy gut microbiome might constitute the colonisation resistance 30 
barrier (CRB) in the gut, inhibiting CDI. 31 
Method CRB drivers pH, short chain fatty acid (SCFA), and oxidation-reduction potential 32 
(ORP) were investigated in vitro using C. difficile NAP1/BI/027. Readouts for inhibitory 33 
mechanisms included germination, growth, toxin production and virulence gene expression. 34 
pH ranges (3 – 7.6), SCFA concentrations (25 – 200mM) and ORP (-300 - +200mV) were 35 
manipulated in brain heart infusion broth cultures under anaerobic conditions to assess the 36 
inhibitory action of these mechanisms.   37 
Results <pH 5.3 completely inhibited C. difficile growth to OD of 0.019 vs. 1.19 for control 38 
pH 7.5. Toxin production was reduced to 25 units vs 3125 units for pH 7.6 (1 in 5 dilutions). 39 
Virulence gene expression reduced by 150 fold compared with pH 7.6 (p<0.05). Germination 40 
and proliferation of spores below pH 6.13 yielded an average OD of 0.006 vs. 0.99 for 41 
control. SCFA were potent regulators of toxin production at 25mM and above (p<0.05). 42 
Acetate significantly inhibited toxin production to 25 units independent of OD (0.8733) vs. 43 
control (OD 0.6 and toxin titer 3125) (p<0.05). ORP did not impact C. difficile growth.  44 
Conclusion This study highlights the critical role that pH has in the CRB, regulating CDI in 45 




Clostridioides difficile (C. difficile) remains a major cause of antibiotic associated diarrhoea 50 
and ulcerative colitis in the healthcare setting (1-3). The gut microbiota plays a vital role in 51 
protection against opportunistic pathogen infections and in many disease states an altered or 52 
dysbiotic gut microbiota is observed (4-7). A competent gut microbiota and environmental 53 
conditions created in the gut forms a barrier to infectious colonisation and is a main 54 
contributor to protect against enteric infection (7). A gut epithelial mucus layer forms a 55 
physical barrier between bacteria and host (8) moderating interaction of opportunistic 56 
pathogens with the gut epithelium and preventing bacterial translocation and infection (9). 57 
The gut microbiota/host interactions are also fundamentally important for training host innate 58 
immune responses to pathogen burden (10).  59 
 60 
There is compelling evidence that oxidation-reduction potentials (ORP), pH and short chain 61 
fatty acids (SCFA) govern microbial colonisation in the gut (3, 4, 10-12).  SCFA have also 62 
been shown to downregulate pathogenic virulence factors in enterohaemorrhagic E. coli 63 
O157:H7 by inhibiting shiga toxin synthesis (13).  These protective mechanisms are 64 
collectively termed the colonisation resistance barrier (CRB). 65 
 66 
Pinpointing an effective therapeutic for C. difficile infection (CDI) is challenging. Current 67 
treatment  for CDI has changed from metronidazole and vancomycin to fidaxomycin and 68 
vancomycin (14-16). Fidaxomycin carries a lower risk of recurrence, but its cost-69 
effectiveness is a topic of debate (17). The main risk factor to CDI is gut microbiota dysbiosis 70 
(12, 18), associated with age and/or administration of broad-spectrum antibiotics. Dysbiosis 71 
leads to an impairment in the CRB yielding opportunities for pathogenic bacteria to 72 
proliferate (3, 11, 12). Maintaining a diverse microbial ecosystem in the colon supports 73 
adequate pH control, optimum ORP and increased SCFA production (19, 20), crucial 74 
elements of the CRB. In the present study, we sought to investigate which elements of the 75 
CRB act as drivers of virulence, germination and growth inhibition of Clostrioides difficile 76 
hypervirulent ribotype 027.  77 
 78 
MATERIALS AND METHODS 79 
Culture conditions for vegetative cells and spores 80 
C. difficile NAP1/BI/027 (BAA-1803, Hall and O’Toole Prevot, ATCC, USA) was prepared 81 
alongside a third passage working cell bank and stored in 10% glycerol at -80°C. Unless 82 
otherwise stated, unsupplemented Brain Heart Infusion (BHI) (Oxoid, UK) broth with a final 83 
pH=7.5 was used for all growth experiments (19, 20). An anaerobic 1% inoculum of ~106 84 
cells was used for each experiment (Don Whitley A45 anaerobic workstation; anaerobic gas 85 
mix (10% CO2, 10% H2, 80% N2)) at 37°C for 48 hours. 86 
 87 
Preparation of spore suspension 88 
A spread of C. difficile ATCC 1803 was carried out on cycloserine/cefoxitin (250 mg/L and 8 89 
mg/L respectively) supplemented BHI agar plates (to select for C. difficile and avoid 90 
contaminant organisms). The plates were incubated at 37°C anaerobically for approximately 91 
7-10 days to encourage sporulation. Colonies were transferred to 1:1 sterile PBS (1%) and 92 
ethanol (100%) for at least 72 hours aerobically to purify the spore suspension. The spores 93 
were then centrifuged (4000 x g for 10 minutes), washed twice and resuspended in sterile 1% 94 
PBS before 1:10 serial dilutions were plated onto blood agar using the modified Miles and 95 
Misra drop plate technique (21) for enumeration. 96 
 97 
 98 
pH experiments 99 
pH ranges reflecting the gastrointestinal tract were examined (pH 3.3-7.6). Sterile BHI broth 100 
was prepared at appropriate pH with 0.1M citric acid and 0.2M disodium phosphate buffer in 101 
10mL glass universals and pre-equilibrated anaerobically overnight. Vegetative cell and 102 
spore suspensions were used at a 1% inoculum of an overnight culture or stored spore 103 
suspension respectively (~106 CFU). Challenged vegetative cells were incubated for 48 hours 104 
anaerobically and spore suspensions for 72 hours anaerobically.  105 
 106 
Continuous culture 107 
A glass 500mL continuous culture vessel was sealed and filled with sterile pH buffered BHI 108 
with an anaerobic gas mix (10% CO2, 10% H2, 80% N2) bubbled through the vessel. Vessel 109 
media (pH=7.5) was heated to 37°C on a hotplate/magnetic stirrer in a laminar flow hood and 110 
inoculum (5mL vegetative cells) added to media and continuously transferred to the vessel at 111 
1 mL/minute. pH was adjusted by feeding appropriate pH buffered BHI (as described in pH 112 
experiments). pH of the vessel was continually monitored; samples were measured for OD 113 
(600nm) and purity streaks were conducted daily. 114 
 115 
Manipulating ORP of BHI broth 116 
100mL sterile, pH buffered BHI broth (pH 5.37, 6.65 and 7.07) was pre-equilibrated 117 
overnight anaerobically. An ORP probe (Cole Parmer, UK) was disinfected in 2% Virkon 118 
(v/v) for 15 minutes before being rinsed in sterile dH20. The ORP probe was calibrated using 119 
pH 4 and pH 7 buffer saturated with quinhydrone.  BHI broth ORP was continually measured 120 
(mV) as filter sterilised 4-5 mL of 2% (v/v) potassium ferricyanide was added to raise the 121 
ORP to + 150mV (19) or above until the level plateaued. The broth was then immediately 122 
inoculated with 1 mL of an overnight culture of C. difficile. Cultures were incubated for 48 123 
hours anaerobically at 37°C. Eh readings were taken at 24 and 48 hours, followed by 124 
measurement of optical density (600nm) at 48 hours. 125 
 126 
SCFA concentrations in BHI broth 127 
BHI broth was buffered to desired pH ranges between pH 3.3-7.6 and sodium salts of SCFA 128 
(acetate, butyrate and propionate) were prepared in a 2M stock solution in H2O and filter 129 
sterilised. Concentrations of SCFA used in experiments ranged from 25 – 300mM.  130 
 131 
Vero cell culture conditions and assay design 132 
African green monkey kidney vero cells (kindly provided by Dr Gillian Douce, University of 133 
Glasgow, UK) were cultured in 75cm2 tissue culture flasks (Starlab, UK) using Eagle’s 134 
Minimum Essential Medium (MEM) (Sigma Aldrich, UK) supplemented with 10% faecal 135 
calf serum and 1% penicillin/streptomycin (complete MEM) with 5% CO2 at 37°C. 96 well 136 
(flat bottomed) microtiter plates were seeded with log 104 vero cells per well and incubated 137 
until a 95% confluent monolayer had formed on the base of the wells. Five-fold serial 138 
dilutions of the cell-free supernatants from pH and SCFA studies were carried out in 139 
complete MEM and exposed to the vero cell monolayer overnight. The monolayers were 140 
observed using a bright field inverted microscope (Olympus, UK) for cell rounding. The 141 
highest dilution of supernatant with less than 30% cell rounding indicated the toxin titer. 142 
Controls were clean BHI broth and MEM. Little to no variation was observed in the triplicate 143 
samples. There were carried out in duplicate to ensure reliability of results and confirmed by 144 




qPCR virulence/colonisation gene analysis 149 
Bacterial cell pellets were treated with RNAprotect (Qiagen, UK) upon conclusion of 150 
experimentation according to the manufacturer’s instructions. The pellets were stored at – 151 
80°C until RNA extraction. RNA was extracted and purified using the RNAeasy kit (Qiagen, 152 
UK) with an additional bead beating step upon addition of RNeasy lysis buffer (Qiagen, UK) 153 
using 0.1mm glass beads (Sigma, UK). DNase treatment was conducted using the RNase free 154 
DNase set following the manufacturer’s instructions (Qiagen, UK). Reverse transcription was 155 
carried out with the Quanti-Tect reverse transcription kit according to manufacturer’s 156 
instructions (Qiagen, UK). In order to quantify virulence gene expression, quantitative PCR 157 
was carried out using PrecisionPLUS 2x qPCR MasterMix premixed with SYBR Green 158 
(PrimerDesign, UK).  The virulence/colonisation genes and primers utilised in this 159 
experiment (22, 23) are described in supplementary file 1 (Life Technologies, UK). The 160 
cycling protocol was 95°C hot start for 2 minutes, x40 cycles of 95°C for 15 seconds and 161 
60°C annealing temperature for 1 minute. Cycle threshold (Ct) values were collected and 162 
percentage expression calculated in comparison to a housekeeping gene (rpoA) by calculation 163 
of ∆∆CT. 164 
 165 
Statistical Analysis 166 
Statistical analysis on data to determine statistical significance between groups was carried 167 
out on Graphpad Prism 7 (GraphPad Software, USA). Shapiro-Wilkes normality test was 168 
conducted to determine distribution of data. Statistical analysis between groups of parametric 169 
data was carried out using a one-way analysis of variance (ANOVA) with Dunnet’s post hoc 170 
test or a Kruskal-Wallis test with Tukey’s post hoc test for multiple comparisons. In cases 171 
where treatment/dose was investigated, a two-way ANOVA with Dunn’s post hoc analysis 172 
was used. Statistical significance was achieved if p < 0.05. 173 
174 
RESULTS 175 
pH strongly influences C. difficile germination, growth, toxin production and colonisation 176 
factor gene expression. 177 
A narrow pH threshold of less than 0.5 pH units differentiated between inhibition of growth 178 
and full confluent growth of C. difficile vegetative cells and spores (Figure 1). Already 179 
revived vegetative cells successfully proliferated at pH=5.83 and above (p<0.01), whilst 180 
spores germinated successfully at pH=6.19 and above (p<0.01). Some of the variability in 181 
results was likely due to noticeable ‘clumping’ in all C. difficile cultures in which confluent 182 
growth had occurred. The OD of the higher pH cultures (pH=6.65, pH=7.07 and pH=7.67) 183 
were not statistically significant from pH=5.83 (p>0.1). Additional studies demonstrated 184 
(Figure 2) no germination for an inoculated spore suspension at pH=5.83 (Fig 2A), and a 185 
shift in lag phase from spore and vegetative cells at pH=6.65 (Fig 2B) and pH=7.76 (Fig 2C). 186 
Inoculation with a spore suspension versus inoculation with a live culture did not result in a 187 
change of maximum optical density (OD) (1.0-1.5). These effects of pH fluctuations on 188 
vegetative cell suspensions were replicated in a continuous culture model (Fig 2D). Lowering 189 
pH below 5.80 resulted in a drop in OD, which was successfully recovered when pH was 190 
raised to above pH=6 in three separate cycles.  191 
 192 
Toxin production was significantly decreased due to the effect of pH=5.37 and 5.83 on C. 193 
difficile (p<0.01, Figure 3). Maximum toxin production was found at pH=7.67, with a step-194 
wise increase in a vegetative cell/spore mixed culture (expressed as the dilution at which the 195 
toxin longer resulted in verocell rounding). Gene expression of TcdA appeared to increase 196 
above pH=6.65 although expression was only significantly higher compared with control at 197 
pH=7.67 (p=0.03, Fig 4A). TcdB expression was not increased when C. difficile was 198 
challenged over the range pH=5.8 to pH=6.19, but was significantly higher at pH=6.65 199 
(p=0.002), pH=7.07 (p=0.007) and pH=7.67 (p=0.0015, Fig 4B). Cwp84 expression 200 
increased significanlty (ten-fold) at pH=7.67 compared with control (p=0.0368, Fig 4C). 201 
CWp84 expression was not significantly increased at any other pH condition in comparison 202 
with the control, which may be linked to fibrous filament morphology found at pH=7.67 203 
(Figure 1). Flagellar protein FliD expression was not detectable at pH=5.83 and pH=6.19, 204 
and was significantly lower at pH=6.65 (p=0.0122) and pH=7.07 (p=0.0024)  (Fig 4D).  205 
 206 
C. difficile toxin production is regulated by acetate 207 
Acetate, propionate and butyrate all had inhibitory effects on C. difficile toxin production at 208 
varying concentrations (Figure 5). Acetate (at all concentrations used) at pH=6.67 did not 209 
influence growth, but significantly inhibited toxin production at 50mM, 100mM and 200mM 210 
(p<0.01, Figure 5). Butyrate reduced C. difficile toxin titer at 25mM, 100mM and 200mM 211 
but did not affect growth (p<0.01). Propionate-treated cell supernatant resulted in high vero 212 
cell rounding at 200mM, with low bacterial OD, but 25mM, 50mM and 100mM significantly 213 
affected toxin burden on vero cell rounding (p<0.01, Figure 5). Experimental error was ruled 214 
out by challenging vero cells with supernatants of three biological replicates and conducting 215 
the assay with three technical replicates.  216 
 217 
ORP has no significant role in the regulation of C. difficile growth 218 
At pH=6.65, increased ORP significantly increased growth (OD) compared with control 219 
(p=0.003) (Figure 6) but no other significant effects were observed when ORP was varied 220 
under experimental conditions. 221 
 222 
  223 
224 
DISCUSSION 225 
Understanding what constitutes the CRB is important to preventing CDI in an ageing 226 
population. This study demonstrates the exquisite sensitivity of C. difficile to subtle changes 227 
around pH=5.67. Increased filamentous morphology was observed at higher pH (pH=6.7 and 228 
above for vegetative cells) which correlates with an increased expression of Cwp84 at 229 
pH=7.67, perhaps due to shorter lag phase. Previous work has shown increased colonisation 230 
gene expression in response to a neutral/basic pH gut environment, observations noted in a 231 
dysbiotic gut (24, 25).  232 
 233 
pH in the colon can reach as low as 5.37–5.83 when consuming a high fibre diet (26, 27). We 234 
demonstrate that manipulation of colonic pH may prevent the colonisation, germination, 235 
growth and toxin production of hypervirulent C. difficile 027. May et al., (1994) highlight the 236 
influence of dietary fibre on the CRB, attributed to increased SCFA production and lowered 237 
pH around the inhibitory ranges we have identified (28). We demonstrate a prolonged lag 238 
phase, decrease in toxin production at pH range 5.37–7.07 and correlation with decreased 239 
expression of the virulence genes tcdA and tcdB. Decreased cytotoxicity and enhanced 240 
colonisation resistance was previously demonstrated in fermentation systems supplemented 241 
with oligosaccharides, which was not attributable Bifidobacteria spp. but may be related to 242 
pH=5.5 maintenance in this model (29). Wetzel and McBride (2019) described increased 243 
toxin A production at pH=5.5 with a solid media matrix. Our results in liquid media suggest a 244 
clear impact of narrow pH thresholds on C. difficile germination and growth. pH impact on 245 
toxin appears to be related to influence on lag phase length and not the impact on the cells 246 
toxin production capacity. 247 
 248 
We demonstrate that C. difficile spore suspension growth was inhibited below pH=6.19 but 249 
proliferation of vegetative cell suspensions above pH=5.67 suggesting that at pH<6.19 250 
germination and outgrowth of spores specifically is prevented. Maximal germination has 251 
previously been shown to occur above pH=6.5 (30). C. difficile can withstand oxidative 252 
environments like S. enterica serotype Typhimurium (31). C. difficile utilises TcdB-induced, 253 
NADPH oxidase (NOX) epithelial cell ROS upregulation to facilitate survival over a wide 254 
range of redox potentials, indicating specialised survival mechanisms in C. difficile at 255 
extreme Eh ranges (32). We observed that extreme positive Eh at the point of inoculation does 256 
not affect C. difficile growth, and that pH drives its ability to proliferate at extreme Eh. 257 
Manipulation of pH in the colon is a plausible mechanism for influencing C. difficile 258 
virulence and pathogenicity regardless ORP perturbations.  259 
 260 
We found significant effects of SCFA on toxin gene expression but no effect on C. difficile 261 
growth. We observed that 100mM sodium butyrate and 100mM sodium propionate increased 262 
tcdA gene expression. Similarly, 100mM sodium butyrate and 50mM sodium acetate 263 
increased tcdB gene expression (Data not shown). However, this was not reflected with toxin 264 
titer in response to the SCFA challenge, which was downregulated.  A similar occurrence was 265 
discussed by Dupuy and Sonenshein, (1998) who found that C. difficile toxin gene expression 266 
was increased as a stringent response to catabolism repression at stationary phase of growth 267 
(33). Increased virulence as a stringent response to stressors is one mechanism by which C. 268 
difficile can utilise a competitive environment to its advantage. This highlights the 269 
importance of identifying colonisation/virulence modifying therapeutics which may alter the 270 
CRB in the colon.  271 
 272 
The limitations of this work are that it does not combine all explored factors and include 273 
complexities of the gut microbiome. Further work is needed to determine if these findings 274 
translate to humans. Future work into the combined effect which incorporates a competent 275 
microbiome, with a detailed understanding of the impact this has on C. difficile germination, 276 
growth and virulence would be a beneficial next step.  277 
 278 
CONCLUSION 279 
 This work highlights colonic environmental mechanisms which can be exploited for 280 
developing CDI therapeutics (34). SCFA and pH, within physiological ranges, are important 281 
to prevent C. difficile colonisation, germination, growth and/or virulence in vitro. Studies 282 
which enhance the CRB in humans at risk of CDI are warranted, particularly if they can 283 
reduce the antibiotic burden, and they may be achievable relatively simply and inexpensively 284 
through dietary means. 285 
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290 
FIGURE LEGENDS 291 
Figure 1: a) C. difficile vegetative cell and spore growth when challenged with pH ranging 292 
from pH 3.36 to pH 7.67 (n = 9). Letters highlight statistically significant groups (p<0.05) 293 
  294 
Figure 2: Vegetative cell vs spore lag phase at A) pH 5.83 B) pH 6.65 and C) pH 7.67 (n=3). 295 
D) pH Effect of pH on C. difficile growth study conducted in chemostat continuous flow 296 
culture showing fluctuations in pH leads to decrease and recovery in OD. Conducted over 35 297 
days with continuous 1 mL/min flow rate of clean, pH buffered BHI broth. 298 
 299 
Figure 3: Toxin titer of C. difficile 027 challenged with pH 5.37 – 7.67 (n=3). Toxin titer 300 
was enumerated as the lowest serial dilutions that resulted in 30 % cell rounding on vero cell 301 
monolayers (expressed as dilution – 1 in 5 increments). Letters highlight statistically 302 
significant groups (p<0.05) 303 
 304 
Figure 4: a) C. difficile tcdA expression at varied pH ranges pH (5.6 - 7.6). b) C. difficile 305 
tcdB expression at varied pH ranges (pH 5.6 – 7.6), c) C. difficile Cwp84 expression at varied 306 
pH ranges (pH 5.6 – 7.6). d) C. difficile FliD expression at varied pH ranges (pH 5.6 – 7.6). 307 
e) C. difficile toxin titer at varied pH (pH 5.3 - 7.6) with control (culture in BHI at pH 7.5). 308 
The experiment was conducted from biological replicates of the effect of pH on C. difficile 309 
growth work (n = 3). This work was conducted from biological replicates of the effect of pH 310 
on C. difficile growth work (n = 3). Each biological replicate was tested in duplicate. Letters 311 
highlight statistically significant groups (p<0.05). 312 
 313 
Figure 5: Quantification of toxin titer and OD (600 nm) of C. difficile 027 in response to 314 
challenge of varied concentrations of SCFA sodium salts of acetate, butyrate and propionate 315 
from 25 – 200 mM (n = 3). Left axis displays toxin titer, enumerated as the lowest serial 316 
dilutions that resulted in 30 % cell rounding on vero cell monolayers (expressed as dilution – 317 
1 in 5 increments). Data is shown in bar chart form. Right axis displays OD (600 nm). Data is 318 
shown in scatterplot form. Letters highlight statistically significant groups (p<0.0001) 319 
 320 
Figure 6: Effect of perturbations in ORP at point of inoculation on C. difficile 027 growth 321 
(n=3). ORP is expressed as ΔEh and results are shown as OD (600 nm). Asterisk highlights 322 
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